Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca Boosts Its COVID-19 Research with More Help From the Public Sector

By Cory Renauer – Updated Jun 9, 2020 at 10:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Britain's biggest pharmaceutical has expanded its agreements with two U.S. government agencies and Vanderbilt University.

Pharmaceutical companies and government agencies working together is an increasingly common theme in the search for effective COVID-19 treatments. On Tuesday, AstraZeneca (AZN -0.13%) licensed coronavirus-neutralizing antibodies from Vanderbilt University, and signed agreements with two U.S. federal agencies that will help test and manufacture them.

Vanderbilt's COVID-19 research effort is in turn funded by four U.S. government agencies through dozens of sub-agencies and institutes, among them the Defense Advanced Research Projects Agency (DARPA) and the Biomedical Advanced Research and Development Authority (BARDA). 

Vial of blood labeled coronavirus.

Image source: Getty Images.

AstraZeneca has licensed six antibodies from a library of more than 1,500 that have been shown in a laboratory setting to interact with SARS-CoV-2 and prevent it from entering host cells. The company is currently running animal tests to determine the most promising pair for advancement to clinical-stage trials in people. 

AstraZeneca says it should be ready to begin human trials with a pair of antibodies within the next two months, and funding those studies should be a breeze. The company also signed an interagency agreement with DARPA and BARDA to support its COVID-19 treatment development effort. 

Once AstraZeneca has selected a pair of antibody candidates for clinical trials, the agencies that helped Vanderbilt researchers isolate them will continue funding their development. Specifically, DARPA and BARDA will help Astra run its trial and manufacture the selected antibodies to be tested.

In addition to its push to develop antibody treatments for COVID-19, AstraZeneca is also one of the companies leading the charge to develop a SARS-CoV-2 vaccine. The company's vaccine candidate, AZD1222, has been licensed from Oxford University, and is already in a phase 2/3 clinical trial with around 10,000 volunteers.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.84 (-0.13%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.